This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Google Scholar Articles by Gautschi, O. Articles by Gandara, D. R. PubMed PubMed Citation Articles by Gautschi, O. Articles by Gandara, D. R. Related Collections Cellular Pathobiology Cellular Pathobiology: Proliferation, Senescence, and Death Therapeutics and Targets: Experimental Therapeutics– Small Molecules

Aurora Kinases as Anticancer Drug Targets

Authors' Affiliations: ¹ Department of Medical Oncology, Bern University Hospital, Bern, Switzerland; ² Cancer Communications and Consultancy Ltd., Cheshire, United Kingdom; and ³ University of California Davis Cancer Center, Sacramento, California

Requests for reprints: David R. Gandara, University of California Davis Cancer Center, 4501 X Street, Suite 3016, Sacramento, CA 95817. Phone: 916-734-3772; Fax: 916-734-7946; E-mail: david.gandara{at}ucdmc.ucdavis.edu.

Abstract

The human aurora family of serine-threonine kinases comprises three members, which act in concert with many other proteins to control chromosome assembly and segregation during mitosis. Aurora dysfunction can cause aneuploidy, mitotic arrest, and cell death. Aurora kinases are strongly expressed in a broad range of cancer types. Aurora A expression in tumors is often associated with gene amplification, genetic instability, poor histologic differentiation, and poor prognosis. Aurora B is frequently expressed at high levels in a variety of tumors, often coincidently with aurora A, and expression level has also been associated with increased genetic instability and clinical outcome. Further, aurora kinase gene polymorphisms are associated with increased risk or early onset of cancer. The expression of aurora C in cancer is less well studied. In recent years, several small-molecule aurora kinase inhibitors have been developed that exhibit preclinical activity against a wide range of solid tumors. Preliminary clinical data from phase I trials have largely been consistent with cytostatic effects, with disease stabilization as the best response achieved in solid tumors. Objective responses have been noted in leukemia patients, although this might conceivably be due to inhibition of the Abl kinase. Current challenges include the optimization of drug administration, the identification of potential biomarkers of tumor sensitivity, and combination studies with cytotoxic drugs. Here, we summarize the most recent preclinical and clinical data and discuss new directions in the development of aurora kinase inhibitors as antineoplastic agents.

This article has been cited by other articles:

				G. C. Prendergast Refining Cytotoxic Therapy: Progress in Generalized Therapeutics for Cancer Cancer Reviews Online Content, April 1, 2008; 2008(4): 7 - 7. [Full Text] [PDF]